ANSWER: C

Rationale:

Herpes zoster (HZ) reactivation is the most common infectious complication of JAK inhibitor therapy, occurring at rates 2 to 4 times higher than with biologic disease-modifying antirheumatic drugs (DMARDs). The pathophysiology involves JAK1 (Janus kinase 1)-dependent suppression of Type I interferon and IFN-gamma (interferon-gamma) signaling, impairing CD8-positive cytotoxic T-cell surveillance of latent varicella-zoster virus (VZV) in dorsal root ganglia. For uncomplicated dermatomal zoster — rash confined to one or two adjacent dermatomes, no ophthalmic involvement, no evidence of dissemination, patient not hospitalized or severely immunocompromised — standard management is prompt oral antiviral therapy with valacyclovir (typically 1,000 mg three times daily for 7 days) or famciclovir. This reduces viral shedding, accelerates healing, and decreases post-herpetic neuralgia risk. For uncomplicated dermatomal HZ, upadacitinib does not universally require interruption; many guidelines permit continuation while monitoring closely for progression. JAK inhibitor hold is reserved for severe, disseminated, or ophthalmologic zoster. Regarding Shingrix: this is a recombinant non-live subunit vaccine (not a live attenuated vaccine), meaning it cannot worsen active zoster; however, administering any vaccine during acute illness — including Shingrix — is generally deferred until resolution because the immune response to vaccination may be suboptimal during active infection, and vaccination timing should be optimized for immunogenicity.

• Option A: Option A is incorrect: dermatomal HZ is not an indication for permanent JAK inhibitor discontinuation; the black box warning identifies serious infections as a risk category requiring monitoring and clinical judgment, not mandatory permanent drug cessation for uncomplicated zoster; Shingrix should not be given during active HZ infection.
• Option B: Option B is incorrect: herpes zoster in a JAK inhibitor-treated patient is not immune reconstitution inflammatory syndrome (IRIS); IRIS occurs when immune function is restored after a period of profound immunosuppression (e.g., antiretroviral initiation in HIV) and an exuberant immune response unmasks or worsens pre-existing infection; withholding antivirals for HZ in an immunosuppressed patient would risk progression to disseminated or post-herpetic neuralgic disease.
• Option D: Option D is incorrect: topical acyclovir cream is not standard of care for dermatomal herpes zoster in any patient, immunosuppressed or otherwise; it does not achieve systemic antiviral concentrations sufficient to treat the neurotropic VZV replication in sensory ganglia; oral valacyclovir or famciclovir is required.
• Option E: Option E is incorrect: a mandatory drug hold until full zoster resolution plus Shingrix completion before restarting is overly restrictive for uncomplicated dermatomal HZ; Shingrix should not be administered during active zoster infection (deferral is appropriate); a 6-week upadacitinib washout requirement before vaccination is not an established standard.

ANSWER: A

Rationale:

Abrocitinib is associated with a dose-dependent decrease in platelet count that is most pronounced at the 200 mg dose and occurs predominantly during the first 4 weeks of therapy. The prescribing information requires platelet count monitoring at baseline and at 4 weeks specifically because of this early thrombocytopenic effect. The label-mandated interruption threshold is a platelet count below 50,000 per microliter — this patient's count of 68,000 is above that formal label threshold and does not by itself trigger mandatory drug hold under prescribing information criteria. However, the magnitude of decline — approximately 70% from a baseline of 224,000 — and the trajectory toward a thrombocytopenic range (below 100,000 per microliter is generally considered thrombocytopenic) represent a clinically significant pattern that warrants intervention in clinical practice, even when the formal label threshold has not yet been crossed. The appropriate response is to interrupt abrocitinib and confirm the platelet count with a repeat measurement to assess trajectory before deciding whether to resume at the same dose, reduce to 100 mg, or discontinue. This scenario illustrates exactly why the 4-week monitoring requirement exists: it is designed to detect early, dose-dependent thrombocytopenia while there is still opportunity to act before the count reaches the formal interruption threshold.

• Option B: Option B is incorrect: a platelet count of 68,000 per microliter is not within the expected reference range for patients on abrocitinib; normal platelet count is approximately 150,000 to 400,000 per microliter; 68,000 represents genuine thrombocytopenia that warrants clinical action and cannot be dismissed as an expected normal finding requiring no intervention.
• Option C: Option C is incorrect: while abrocitinib does affect platelet production through JAK1 (Janus kinase 1) activity in megakaryocyte differentiation pathways — with some contribution from JAK2 activity at higher doses — this finding does not constitute an absolute contraindication to all future JAK inhibitor use; dose reduction to 100 mg may resolve the thrombocytopenia; the blanket prohibition on all future oral targeted agents is clinically unjustified based on this episode alone.
• Option D: Option D is incorrect: abrocitinib-associated thrombocytopenia is a dose-dependent effect on platelet production (a pharmacodynamic mechanism), not immune thrombocytopenic purpura (ITP) from hapten formation; the distinction matters clinically because ITP is treated with immune suppression (IVIG, steroids), while abrocitinib-associated thrombocytopenia is managed by dose adjustment; administering IVIG without confirming the mechanism would be premature and potentially harmful.
• Option E: Option E is incorrect: abrocitinib is a JAK1 inhibitor, not a PDE4 inhibitor; PDE4 inhibition describes apremilast's mechanism; abrocitinib does not cause hypersplenism from portal hypertension; this mechanism is pharmacologically fabricated.

ANSWER: E

Rationale:

This clinical scenario requires applying the FDA's post-ORAL Surveillance JAK inhibitor risk framework to a patient who has developed a new malignancy while on therapy. The ORAL (Oral Rheumatoid Arthritis triaLs) Surveillance trial demonstrated that tofacitinib was associated with a higher overall malignancy incidence compared to TNF inhibitors, with the signal driven substantially by non-melanoma skin cancer (NMSC) — particularly squamous cell carcinoma (SCC) — and lung cancer (elevated in smokers). The FDA black box warning explicitly lists NMSC among the malignancies of concern and includes patients with a history of malignancy among those in whom JAK inhibitors should be avoided when alternatives exist. This patient has now acquired a concrete new malignancy (SCC) that was specifically elevated in the ORAL Surveillance data, combined with his pre-existing 45 pack-year past smoking history — a second avoidance criterion. Together, these factors trigger a mandatory risk-benefit reassessment. The appropriate management involves: oncology consultation regarding ongoing cancer surveillance and immunosuppression safety; dermatology engagement for enhanced skin cancer surveillance; consideration of transitioning to vedolizumab, which is approved for UC maintenance, has no malignancy signal, and provides gut-selective immunosuppression without the ORAL Surveillance-derived cancer risk; and shared decision-making that explicitly names the new label avoidance criteria. Tofacitinib is not mandatorily discontinued by this event, but continuing it without reassessment would be clinically inappropriate.

• Option A: Option A is incorrect: the ORAL Surveillance malignancy signal and the FDA black box warning specifically include non-melanoma skin cancer including SCC; the claim that NMSC is excluded from the black box warning and is not relevant to the prescribing decision is directly contrary to the labeling.
• Option B: Option B is incorrect: permanent mandatory discontinuation of all systemic immunosuppression after any new malignancy is not the standard approach; the clinical reality requires nuanced risk-benefit re-evaluation; patients with UC in remission may have few therapeutic options beyond systemic agents, and 5-aminosalicylates alone are often insufficient for maintaining remission in moderate-to-severe UC.
• Option C: Option C is incorrect: surgical cure of SCC does not eliminate the pharmacological risk signal; the concern is not just this individual cancer but the elevated ongoing risk of future skin cancers in a patient who continues JAK inhibitor therapy — particularly one with a heavy smoking history; the statement that no oncology consultation is required understates the appropriate clinical response.
• Option D: Option D is incorrect: the ORAL Surveillance malignancy data reflects outcomes in the overall trial population; attributing individual cancers to prior smoking to "absolve" tofacitinib is not pharmacologically valid; the drug's contribution to cancer risk is independent of whether the individual cancer has a plausible alternative cause, and the FDA label does not provide such a causal exclusion.

ANSWER: B

Rationale:

This question tests the ability to correctly attribute a clinical adverse effect to the right mechanism by distinguishing deucravacitinib from apremilast. The prominent early gastrointestinal adverse effect profile — nausea, diarrhea, and headache in up to approximately 30% of patients during the first 4 to 6 weeks — is a well-characterized class effect of apremilast, the PDE4 (phosphodiesterase 4) inhibitor. This profile arises because PDE4 inhibition increases intracellular cAMP (cyclic adenosine monophosphate) in enteric neurons and intestinal smooth muscle, altering gut motility and secretion. Apremilast is specifically prescribed with a 5-day dose titration schedule to mitigate these GI effects, and they typically resolve with continued therapy. Deucravacitinib, by contrast, is a TYK2 (tyrosine kinase 2) allosteric inhibitor that works through an entirely different mechanism — binding the JH2 (JAK homology 2) pseudokinase regulatory domain of TYK2 and stabilizing it in an autoinhibited conformation. Deucravacitinib does not inhibit PDE4 and does not carry the apremilast-associated GI effect profile as a labeled class effect. Attributing this patient's GI symptoms to "a PDE4 class effect" — and suggesting a retroactive titration schedule designed for apremilast — would represent a mechanistic error. Her GI symptoms at week 5 require standard evaluation (infectious etiology, irritable bowel syndrome, dietary factors) rather than attribution to a pharmacological mechanism that does not apply to deucravacitinib.

• Option A: Option A is incorrect: the 5-day titration schedule is specific to apremilast's PDE4-mediated GI effect and has no pharmacological rationale for deucravacitinib; deucravacitinib does not produce nausea and diarrhea through PDE4 inhibition; retroactively applying an apremilast-specific mitigation strategy to a different drug class is mechanistically incorrect.
• Option C: Option C is incorrect: deucravacitinib-induced drug colitis from TYK2-mediated IL-10 suppression in intestinal epithelium is not an established clinical entity; while TYK2 does pair with the IL-10 receptor and IL-10 has gut mucosal homeostatic functions, a "drug-induced colitis as a class effect of all TYK2 inhibitors" is not a recognized labeled adverse effect of deucravacitinib.
• Option D: Option D is incorrect: cytokine release reactions from rapid IL-23 suppression in GALT (gut-associated lymphoid tissue) causing GI symptoms is a fabricated mechanism; routine prophylactic antihistamine use during deucravacitinib therapy is not a recommended or evidence-based practice.
• Option E: Option E is incorrect: while CYP3A4-mediated drug interactions can raise deucravacitinib exposure, GI symptoms alone are not a reliable indicator of supratherapeutic drug levels from a specific interaction; this clinical presentation does not provide evidence of a CYP3A4 interaction, and holding the drug pending medication reconciliation is not the first-line response to mild GI symptoms at week 5.

ANSWER: D

Rationale:

The ozanimod prescribing information identifies specific cardiac conditions as absolute contraindications: second- or third-degree AV block, sick sinus syndrome, and sinoatrial block (unless the patient has a functioning pacemaker). First-degree AV block — defined as a PR interval greater than 200 ms without dropped beats — is not listed as an absolute contraindication in ozanimod's labeling. However, the prescribing information does require first-dose monitoring with an ECG and heart rate assessment after the first dose in patients at risk for cardiac conduction abnormalities, including those with baseline bradycardia (defined as heart rate below 55 bpm in labeling context), pre-existing cardiac conduction disease, or concurrent use of drugs that lower heart rate. This patient has both: a resting heart rate of 52 bpm (below the 55 bpm threshold that triggers first-dose monitoring per labeling) and a prolonged PR interval of 220 ms, representing a mild conduction abnormality that places him at higher risk for meaningful bradycardia or AV conduction prolongation from ozanimod's S1P1/S1P3-mediated GIRK (G protein-coupled inward rectifier potassium) channel activation on nodal tissue. The clinically correct approach is cardiology evaluation to assess the clinical significance of his ECG findings, followed by first-dose monitoring if cardiology determines ozanimod can proceed; ozanimod is not automatically excluded by first-degree AV block alone.

• Option A: Option A is incorrect: first-degree AV block is not an absolute contraindication to ozanimod; the prescribing information lists second-degree and third-degree AV block as absolute contraindications, not first-degree; labeling tofacitinib as the only appropriate oral alternative overstates the restriction.
• Option B: Option B is incorrect: dismissing a resting heart rate of 52 bpm and PR of 220 ms as normal athletic variation without any cardiac evaluation before ozanimod initiation ignores the prescribing information's first-dose monitoring requirements for patients with baseline bradycardia and conduction findings; the labeling specifically triggers monitoring at heart rates below 55 bpm.
• Option C: Option C is incorrect: there is no absolute FDA-labeled ECG cutoff of 200 ms PR interval above which ozanimod is prohibited; the absolute contraindications are second- and third-degree AV block; first-degree AV block with PR of 220 ms does not constitute a categorical exclusion.
• Option E: Option E is incorrect: the physiological explanation for bradycardia in a young person does not eliminate the pharmacological relevance to ozanimod's cardiac mechanism; S1P1/S1P3 GIRK channel activation on nodal tissue will produce the same bradycardia and AV conduction slowing regardless of whether the baseline bradycardia is athletic or pathological; age-based reassurance is not a substitute for the required cardiology evaluation and first-dose monitoring.

ANSWER: A

Rationale:

This question applies the baricitinib-probenecid drug interaction to a clinical prescribing scenario. Baricitinib is eliminated through a combination of CYP3A4-mediated hepatic metabolism and OAT3 (organic anion transporter 3)-mediated renal tubular secretion. Probenecid's mechanism as a uricosuric agent involves blocking URAT1 (proximal tubular urate reabsorption transporter 1) to increase uric acid excretion, but probenecid is also a potent OAT3 inhibitor — a property that causes it to block baricitinib's renal elimination pathway simultaneously, markedly increasing baricitinib plasma exposure. The baricitinib prescribing information explicitly contraindicates co-administration with probenecid. For this patient who needs urate-lowering therapy, xanthine oxidase inhibitors — allopurinol or febuxostat — are the appropriate alternatives. These agents work by inhibiting xanthine oxidase (the enzyme that converts hypoxanthine to xanthine and xanthine to uric acid), thereby reducing urate production rather than increasing urinary excretion. Neither allopurinol nor febuxostat interacts with OAT3 or CYP3A4 in a manner that affects baricitinib pharmacokinetics at standard doses, making them safe choices for concurrent use.

• Option B: Option B is incorrect: the claim that baricitinib is primarily eliminated by CYP3A4-mediated hepatic metabolism without meaningful OAT3 contribution is pharmacologically inaccurate; OAT3-mediated renal elimination is a well-documented and clinically significant pathway for baricitinib, which is specifically why the probenecid interaction is contraindicated rather than dose-adjustable.
• Option C: Option C is incorrect: probenecid does not produce only transient OAT3 competition that normalizes at steady state; OAT3 inhibition by probenecid is sustained throughout the dosing interval; baricitinib steady-state levels are continuously elevated during concurrent probenecid use, not only transiently affected during a loading phase.
• Option D: Option D is incorrect: allopurinol inhibits xanthine oxidase, not an enzyme involved in baricitinib's metabolic pathway; baricitinib does not have an active metabolite whose metabolism depends on xanthine oxidase; the claimed interaction between allopurinol and baricitinib via xanthine oxidase inhibition is pharmacologically fabricated.
• Option E: Option E is incorrect: baricitinib does not cause hyperuricemia through JAK2-mediated impairment of renal uric acid secretion via JAK2-STAT5 signaling; this mechanism is fabricated; gout flares in a patient on baricitinib are not attributable to the drug's pharmacological mechanism, and stopping baricitinib is not a management strategy for gout.

ANSWER: C

Rationale:

Among the approved JAK inhibitors, upadacitinib is the only one with FDA approval for Crohn's disease. Tofacitinib is approved for UC but not Crohn's disease; baricitinib is approved for RA, alopecia areata, and atopic dermatitis but not IBD; filgotinib has EU approval for UC and RA but has not received FDA approval for any indication (it received a complete response letter from the FDA due to concerns about male reproductive toxicity from high-dose animal studies, despite subsequent human fertility data showing no impairment). Upadacitinib's Crohn's disease approval was based on the U-EXCEED and U-EXCEL phase 3 trials, which demonstrated clinical remission rates of approximately 39 to 49% at 12 weeks induction versus 14 to 22% for placebo. The approved induction dose for Crohn's disease is 45 mg once daily for 12 weeks — longer than the 8-week UC induction — reflecting the deeper transmural inflammation and greater JAK1 (Janus kinase 1) inhibition required for transmural healing in Crohn's disease compared to mucosal-predominant UC. After achieving clinical response, maintenance dosing transitions to 15 mg or 30 mg once daily. This patient has met the criteria: two prior biologic failures (infliximab, vedolizumab), preference for oral therapy, and no JAK inhibitor avoidance criteria (young age without cardiovascular risk, no malignancy, no cardiac issues).

• Option A: Option A is incorrect: tofacitinib is not approved for Crohn's disease; its FDA-approved IBD indication is limited to ulcerative colitis; prescribing tofacitinib for Crohn's disease would constitute off-label use that is not supported by approved labeling or the evidence base.
• Option B: Option B is incorrect: baricitinib does not carry an FDA-approved indication for Crohn's disease; its selectivity for JAK1/JAK2 does not translate into an IBD approval; the described induction-maintenance regimen for Crohn's disease is fabricated.
• Option D: Option D is incorrect: the statement that no JAK inhibitor is approved for Crohn's disease is factually incorrect as of current approvals; upadacitinib received FDA approval for Crohn's disease and is an available oral targeted therapy option for this patient.
• Option E: Option E is incorrect: filgotinib has not received FDA approval for any indication; it was not approved for Crohn's disease in the United States; the superiority claim based on reproductive safety data compared to upadacitinib does not reflect current FDA approval status.

ANSWER: E

Rationale:

This clinical scenario requires applying pregnancy safety data to two distinct medications with different risk profiles. Methotrexate is a well-established teratogen and abortifacient; it is a folate antagonist that interferes with DNA synthesis during organogenesis and is absolutely contraindicated in pregnancy. Standard guidance requires stopping methotrexate at least 3 months before conception to allow adequate washout and folate repletion. Tofacitinib's pregnancy safety profile is based on animal reproduction studies showing embryotoxicity, fetotoxicity, and teratogenicity at doses higher than clinical doses in rats and rabbits, combined with very limited human pregnancy data. JAK-STAT signaling plays important roles in early embryonic development, implantation, and placental function, providing a plausible biological mechanism for teratogenic risk. The prescribing information states that tofacitinib is not recommended during pregnancy, and women of reproductive potential should use effective contraception during treatment and for a period after discontinuation. Small molecules like tofacitinib generally cross the placenta more readily than large-molecule biologic antibodies (which require active FcRn transport, predominantly in the second and third trimester). For disease control during pregnancy, certolizumab pegol is the preferred TNF inhibitor: it lacks the Fc region required for active FcRn-mediated placental transfer, resulting in minimal fetal drug exposure even in the third trimester, and it has a robust pregnancy registry dataset.

• Option A: Option A is incorrect: tofacitinib should be discontinued before conception, not continued; the claim that JAK1/JAK3 inhibition has no teratogenic potential because it is intracellular is not supported by the prescribing information or animal reproductive data; while methotrexate discontinuation timing is correctly stated, the tofacitinib guidance is wrong.
• Option B: Option B is incorrect: the premise that JAK-STAT signaling is absent from the placenta in the first trimester and that fetal organ development is unaffected by JAK inhibitors in the first 12 weeks is biologically incorrect; JAK-STAT signaling is critical for implantation, trophoblast invasion, and early embryonic development, making the first trimester a period of particular vulnerability.
• Option C: Option C is incorrect: tofacitinib is a small molecule with a molecular weight of approximately 312 Da and passive diffusion characteristics that allow placental crossing; it does not require FcRn-mediated active transport to cross the placenta; the claim that its small-molecule nature prevents placental transfer is pharmacokinetically incorrect.
• Option D: Option D is incorrect: tofacitinib and methotrexate are not FDA pregnancy category A drugs; such a designation would require controlled human studies showing no fetal risk in the first trimester, which does not exist for either agent; the FDA pregnancy category system was replaced by the PLLR (Pregnancy and Lactation Labeling Rule) in 2015, and both agents carry prescribing information discouraging pregnancy use.

ANSWER: B

Rationale:

All JAK inhibitors produce increases in serum lipid levels — LDL cholesterol and total cholesterol — typically within the first 4 to 8 weeks of therapy as a mechanism-based class effect. The proposed pathophysiology involves restoration of JAK-STAT-mediated hepatic lipid metabolism that was suppressed by the chronic inflammatory state of active RA: as disease activity is controlled, hepatic lipoprotein synthesis regulation normalizes, raising serum lipid levels. This patient's LDL rise from 118 to 145 mg/dL (approximately 23%) is consistent with this expected class effect. The clinical management question is whether to initiate statin therapy. His 10-year ASCVD risk of 18% places him in the high-risk category (≥7.5% is the threshold for statin benefit discussion per ACC/AHA guidelines; ≥20% is very high risk). For a 66-year-old man with an 18% ASCVD risk, an LDL of 145 mg/dL, and a new drug with established additive cardiovascular signals (ORAL Surveillance data showing elevated MACE rates with baricitinib-class agents in older, higher-risk patients), the clinical practice guidance is clear: statin therapy should be initiated at this visit at a risk-appropriate intensity (moderate- to high-intensity statin for an 18% ASCVD risk with elevated LDL). Baricitinib does not need to be discontinued for this lipid change; lipid management is the appropriate response.

• Option A: Option A is incorrect: the LDL threshold of 190 mg/dL applies to familial hypercholesterolemia-driven decisions where high-intensity statins are indicated regardless of risk score; for this patient with an 18% ASCVD risk score and an LDL of 145 mg/dL, deferring statin therapy until LDL reaches 190 mg/dL is not consistent with current cardiovascular risk management guidelines or the JAK inhibitor-specific monitoring recommendations.
• Option C: Option C is incorrect: there is no prescribing information LDL threshold of 140 mg/dL that requires baricitinib cessation; LDL elevation from JAK inhibitors is managed by lipid-lowering therapy, not drug discontinuation; mandating baricitinib cessation for an LDL of 145 mg/dL is not a clinical standard.
• Option D: Option D is incorrect: baricitinib does not permanently reduce hepatic LDL receptor upregulation through irreversible JAK2 inhibition; the lipid effect is pharmacodynamic and reversible; statins are effective for managing JAK inhibitor-associated LDL elevation in clinical practice; PCSK9 inhibitors as the sole effective option is not established.
• Option E: Option E is incorrect: JAK inhibitor-associated lipid elevation is not a transient inflammatory resolution artifact that resolves at 3 months without intervention; the elevation is a sustained class effect that persists during ongoing therapy; deferring all evaluation to a 6-month repeat lipid panel without initiating appropriate pharmacological management is not consistent with evidence-based cardiovascular risk management.

ANSWER: D

Rationale:

This clinical scenario applies the comparative efficacy and regulatory positioning of deucravacitinib versus apremilast in a biologic-naive patient with moderate-to-severe plaque psoriasis who has failed methotrexate and prefers oral therapy. Deucravacitinib is approved for moderate-to-severe plaque psoriasis without a prior biologic failure requirement — unlike JAK inhibitors in rheumatological indications (RA, PsA, AS), which require prior TNF inhibitor failure per FDA labeling. This distinction is clinically critical: deucravacitinib can be prescribed as a first oral option after conventional DMARD failure in psoriasis. In the POETYK (Psoriasis Outcomes and Endpoints Trial of TYK2 inhibitor) PSO-1 and PSO-2 phase 3 trials, deucravacitinib achieved PASI 75 response rates of approximately 58 to 62% at week 16, significantly superior to apremilast's approximately 31 to 38% in direct head-to-head comparison. Furthermore, deucravacitinib does not carry the class-wide FDA black box warnings for serious infections, malignancy, MACE (major adverse cardiovascular events), and VTE (venous thromboembolism) that apply to JAK inhibitors, because its TYK2-selective allosteric mechanism avoids the JAK1, JAK2, and JAK3 inhibition responsible for those safety signals. For this patient who wants the most effective available oral agent, has no contraindications, and has met the conventional DMARD failure threshold, deucravacitinib is the pharmacologically superior and appropriately positioned choice.

• Option A: Option A is incorrect: deucravacitinib's efficacy superiority over apremilast was demonstrated in biologic-naive and biologic-experienced patients in the POETYK trials; there is no subgroup analysis showing the advantage disappears in biologic-naive patients; deucravacitinib does not require prior biologic failure for psoriasis use.
• Option B: Option B is incorrect: deucravacitinib does not require prior failure of both methotrexate and a biologic per FDA labeling for psoriasis; the prior biologic failure requirement applies to JAK inhibitors in rheumatological indications; deucravacitinib in psoriasis has no such sequencing mandate.
• Option C: Option C is incorrect: deucravacitinib and apremilast are not equivalent first-line oral options; they have meaningfully different efficacy profiles with deucravacitinib demonstrating statistically superior PASI 75 response in head-to-head trials; age and renal function are not the primary determinants of choosing between them.
• Option E: Option E is incorrect: methotrexate's GI intolerance does not predict GI intolerance to deucravacitinib; methotrexate causes GI side effects through folate metabolism disruption and direct mucosal toxicity, while deucravacitinib's GI profile is not characterized by the same class-based nausea and diarrhea seen with apremilast (the PDE4 inhibitor); there is no pharmacological basis for predicting cross-intolerance between these mechanistically unrelated drugs.

ANSWER: A

Rationale:

Macular edema is a recognized class adverse effect of S1P receptor modulators, including ozanimod, siponimod, and fingolimod (the first-generation non-selective S1P modulator). The pathophysiology involves S1P receptor modulation affecting vascular permeability in the macula — the central area of the retina responsible for detailed vision. The ozanimod prescribing information requires an ophthalmic examination before initiation to establish baseline and recommends evaluation in any patient who develops visual disturbance during therapy. If macular edema is confirmed on ophthalmological examination, ozanimod should be discontinued because continued S1P receptor modulation could worsen the edema and cause permanent visual damage. Prompt ophthalmology referral is therefore the correct and urgent next step. Patients with pre-existing conditions that increase macular edema risk — diabetes mellitus, uveitis, prior macular disease — warrant particular vigilance, but macular edema can occur in patients without these risk factors, as in this scenario.

• Option B: Option B is incorrect: the described mechanism — ozanimod crossing the blood-retinal barrier and inhibiting S1P5 on retinal ganglion cells — is not the established mechanism for ozanimod-associated visual changes; macular edema from vascular permeability changes is the documented adverse effect, not a pharmacologically expected direct S1P5 neuronal effect that is reversible without drug interruption; dismissing the finding without ophthalmology referral risks permanent vision loss.
• Option C: Option C is incorrect: ozanimod does not cause hypertension through S1P2-mediated peripheral vasoconstriction as the mechanism for macular edema; the described blood pressure management protocol before ophthalmology evaluation is fabricated and would dangerously delay appropriate care for a patient with sight-threatening macular pathology.
• Option D: Option D is incorrect: blurred vision with funduscopic macular changes during ozanimod therapy is not attributed to refractive error unmasked by peripheral lymphopenia; lymphopenia does not cause refractive changes; dismissing funduscopically identified macular changes as a refractive issue without urgent ophthalmology evaluation could result in untreated macular edema and permanent vision impairment.
• Option E: Option E is incorrect: ozanimod does not cause CNS demyelination through S1P5-mediated oligodendrocyte dysfunction as a mechanism for visual symptoms; S1P5 expression on oligodendrocytes and lymphocytes is relevant to MS biology, but ozanimod-associated visual symptoms in UC patients reflect macular edema, not CNS demyelination; progressive multifocal leukoencephalopathy (PML) is a risk associated with natalizumab's CNS immunosuppression mechanism, not with ozanimod's gut-lymphocyte-trapping mechanism.